action of glp 1 agonist Possible mechanisms of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight glp-1_analogs [TUSOM | Pharmwiki]

FDA-Approved Indications GLP-1 agonists (also known as GLP-1 receptor agonists, incretin mimetics, or GLP-1 analogs) represent a class of medications used to treat T2DM and, in some cases,

Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)

GLP-1 drugs could rapidly evolve beyond current use as diabetes and weight loss medications, with new research pointing to potential benefits in cancer, ageing, addiction, osteoarthritis and heart health

Although most of the studies reported an association between GLP-1 RA and increased residual gastric contents, evidence linking these medications to a statistically significant rise in regurgitation or aspiration events remains highly inconsistent

Novo Nordisk and Ascendis Pharma have partnered to develop a long-acting, monthly GLP-1 drug